Clover Biopharmaceuticals’ Covid-19 adjuvant could benefit over IMV’s and Novavax’s vaccines due to its use of Dynavax Technologies’ FDA-approved adjuvant. However, it is too early to predict a clear leader among the three vaccines due to data gaps such as reproduction platforms to be used in manufacturing, as well as how the spike protein antigen is constructed.
On 25 May, Novavax’s stock jumped to 17% during trading hours after announcing it had enrolled the first participants in its clinical trials, while IMV’s stock rose 20% on 21 May after announcing plans to enter clinical development. Dynavax was up 14% on 24 March upon its collaboration announcement with Clover Biopharmaceuticals. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
